nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

25.10.2021 | ASCO 2021 | short review

Best of ASCO 2021—bladder cancer

verfasst von: Karl Mayrhofer, MD, Dora Niedersüß-Beke, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Summary

Three trials presented at the meeting investigated the incorporation of immunotherapy into a multimodal bladder-sparing treatment approach. The results of these phase 2 trials are so far promising with most patients achieving complete remission (CR) and estimated bladder-intact disease-free survival (BIDFS) in these patients ranges between 73 and 88%. Additionally, the up to 5-year follow-up data from the KEYNOTE-052 study were discussed. The results confirm the efficacy of pembrolizumab as first-line monotherapy in cisplatin-ineligible patients with a programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10.

Vorheriger Artikel ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

Nächster Artikel ASCO 2021–Gastroesophageal tumor highlights

O’Donnell PH, Balar AV, Vuky J, Castellano D, Bellmunt J, Powles T, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol. 2021;39(15_suppl):4508.CrossRef

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine. 2020;383(13):1218–30.CrossRef

Balar AV, Milowsky MI, O’Donnell PH, Alva AS, Kollmeier M, Rose TL, et al. Pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4504.CrossRef

Garcia del Muro X, Valderrama BP, Medina A, Cuellar MA, Etxaniz O, Gironés Sarrió R, et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial. J Clin Oncol. 2021;39(15_suppl):4505.CrossRef

Galsky MD, Daneshmand S, Chan KG, Dorff TB, Cetnar JP, Neil OB, et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257. J Clin Oncol. 2021;39(15_suppl):4503.CrossRef

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–14.CrossRef

Titel: Best of ASCO 2021—bladder cancer
verfasst von: Karl Mayrhofer, MD
Dora Niedersüß-Beke, MD, MBA
Publikationsdatum: 25.10.2021
Verlag: Springer Vienna
Schlagwort: ASCO 2021
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00765-7

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

Unresectable pleural mesothelioma—hope or still an unmet medical need?

Best of ASCO 2021

Value of autophagy-related gene 5 (ATG5) expression as a prognostic marker in adults with newly diagnosed acute lymphoblastic leukaemia (ALL)

Neuroendocrine neoplasms of the lung: a pathology update

Pancytopenia—a diagnostic challenge?